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The number of immunizations recommended for children in Europe in the first 2 years of life 2 
has increased dramatically over time. Simplifying immunization schedules through the use of 3 
combination vaccines reduces painful injections for the infant and has been shown to lead to 4 
higher rates of compliance with complex vaccination schedules, while simultaneously 5 
protecting against several diseases in a short period of time [1-4]. DTaP5-HB-IPV-Hib 6 
(diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, 7 
Haemophilus influenzae type b (Hib) conjugate, and hepatitis B [recombinant] vaccine; 8 
Vaxelis®, MCM Vaccine B. V., Leiden, The Netherlands), is a new hexavalent vaccine 9 
developed to provide protection against six childhood infectious diseases: diphtheria, 10 
tetanus, pertussis, hepatitis B, polio, and Hib. It is a ready-to-use, preservative-free, fully 11 
liquid preparation with the potential to minimize errors related to inadequate reconstitution of 12 
Hib. It is a combination of existing antigens from vaccines already licensed in Europe and/or 13 
in the United States (Table 1a).  14 
 15 
In four phase 3 studies of the vaccine, various primary schedules were studied with 16 
coadministration of rotavirus vaccine, pneumococcus 13-valent conjugate vaccine (PCV-13), 17 
and the measles, mumps, rubella (MMR) vaccine [5-8]. In some European Union countries, 18 
including Ireland, Iceland, Spain, and Greece, the childhood vaccination calendar includes 19 
administration of meningococcus group C conjugate (MCC) vaccines with the primary series. 20 
In 2011, the United Kingdom (UK) childhood vaccination schedule was an accelerated 3-21 
dose primary series of a pentavalent (diphtheria, tetanus, pertussis [acellular, component 22 
DTaP], poliomyelitis [inactivated IPV], and Hib) vaccine at 2, 3, and 4 months of age. The 23 
second and third doses were given concomitantly with an MCC vaccine, followed by a 24 
booster dose with a combined Hib-MCC vaccine at 12 months of age. PCV-13, a CRM197 25 
conjugated vaccine, was also administered concomitantly at 2 and 4 months of age with a 26 
booster dose at 12 months of age. The UK schedule changed in June 2013 (after this study 27 




and again in July 2016, when infant meningococcus group C immunization was discontinued 29 
completely. 30 
 31 
The present study evaluates the concomitant administration of DTaP5-HB-IPV-Hib with two 32 
different MCC vaccines. The primary objective was to describe anti-meningococcus group C 33 
seroprotection rates (SPR) in healthy infants aged 5 months following 2 doses of either an 34 
MCC-detoxified tetanus toxin vaccine (MCC-TT; NeisVac-C®, Baxter AG, Wien, Austria) or 35 
an MCC-Corynebacterium diphtheriae CRM197 protein vaccine (MCC-CRM; Menjugate®, 36 
Novartis Vaccine and Diagnostics, S.R.L., Siena, Italy) given at 3 and 4 months of age 37 
concomitantly with second and third doses of DTaP5-HB-IPV-Hib. In addition, primary 38 
seroprotection rates after the primary series, geometric mean titers (GMTs), or geometric 39 
mean concentrations (GMCs) to the antigens in DTaP5-HB-IPV-Hib, and anti-40 
meningococcus group C seroprotection rates after only one dose of MCC were described in 41 
the two study groups, as well as following the Hib-MCC vaccine given in the booster phase. 42 
Post-primary and post-booster seroresponses in the groups randomised to receive the two 43 
different MCC vaccines at 3 and 4 months of age were compared in a post hoc analysis. 44 
Safety data are also reported. 45 
 46 
Materials & Methods 47 
This was a randomised, open-label, multicentre trial evaluating two MCC vaccines when 48 
given concomitantly with DTaP5-HB-IPV-Hib (EudraCT 2011-002413-11). The study was 49 
conducted at 11 sites in the UK and was carried out in accordance with Good Clinical 50 
Practice guidelines under the favourable opinion of the National Research Ethics Service 51 
Committee South West – Central Bristol (11/SW/0328) and with UK Medicines and 52 
Healthcare Product Regulatory Agency approval.  53 
 54 




Invitation letters were sent to the parents of children due for their routine immunizations, and 56 
parents who expressed an interest in enrolling their child in the study were called to ensure 57 
eligibility. Exclusion criteria included participation in another trial involving an investigational 58 
compound or device, known immunosuppression, immunodeficiency or other chronic illness, 59 
administration of blood products, previous vaccination with antigens being administered as 60 
part of the study, or illness relating to these diseases and allergic reactions to any vaccine 61 
components. 62 
 63 
Eligible infants were either visited in their homes or seen at the hospital or clinical research 64 
facility for their visits. Informed consent was obtained from at least one parent before any 65 
study procedures commenced. 66 
 67 
Visits and vaccines 68 
A total of 284 healthy infants aged 46 to 74 days were recruited over a 7-month period and 69 
randomised (1:1 based on balanced permuted blocks of randomization ranging in size from 70 
4 to 8 and stratified by site) to receive either the MCC-TT vaccine (MCC-TT group) or the 71 
MCC-CRM vaccine (MCC-CRM group). An overview of the visit schedule is provided in 72 
Table 1b. The study was divided into two parts: a primary vaccination phase (2 to 5 months 73 
of age), and a booster phase (12 to 13 months of age). Regardless of group assignment, all 74 
participants were scheduled to receive the following: 75 
Primary phase: DTaP5-HB-IPV-Hib and PCV-13 at 2 months of age; followed by DTaP5-76 
HB-IPV-Hib and an MCC vaccine at 3 months of age; and DTaP5-HB-IPV-Hib, MCC, 77 
and PCV-13 vaccines at 4 months of age. 78 
Booster phase: MMR and Hib-MCC vaccines at 12 months of age. 79 
 80 
Blood samples were obtained at 2, 4, and 5 months of age during the primary phase, and at 81 





Serological assays 84 
Serology was performed at three different laboratories as follows. 85 
 86 
Serum bactericidal antibody with rabbit complement assay (rSBA). Meningococcal 87 
serogroup C antibody levels were measured at the Vaccine Evaluation Unit, Public Health 88 
England, Manchester, UK, using an internationally standardized serum bactericidal antibody 89 
assay with baby rabbit complement (rSBA) [9, 10]. rSBA titers were expressed as the 90 
reciprocal of the final serum dilution giving ≥50% killing at 60 minutes as compared with 91 
control (heat-inactivated complement, meningococci, and no unknown serum). The lower 92 
limit of quantitation (LLOQ) for the rSBA assay was 4. For immunogenicity calculations, 93 
values below the LLOQ were replaced by half of the LLOQ (i.e., were assigned a titer of 2). 94 
 95 
Radioimmunoassay for antibodies to Hib capsular polysaccharide (PRP). A standard 96 
Farr technique radioimmunoassay (RIA) was used to detect antibody to Hib capsular 97 
polysaccharide [11]. These assays were performed at Pharmaceutical Product 98 
Development, Vaccines and Biologics Laboratory Department, Wayne, Pennsylvania, USA. 99 
 100 
Enhanced chemiluminescence assay for antibodies to hepatitis B surface antigen 101 
(HBsAg). Antibody concentrations to hepatitis B were measured with a hepatitis-B–102 
enhanced chemiluminescence assay that detected total antibody to human plasma-derived 103 
HBsAg (Pharmaceutical Product Development, Vaccines and Biologics Laboratory 104 
Department, Wayne, Pennsylvania, USA) [11,12].  105 
 106 
Micrometabolic inhibition tests for antibodies to diphtheria and poliovirus. Antibody 107 
concentrations to diphtheria toxin and titers to poliovirus types 1, 2, and 3 were measured at 108 
Global Clinical Immunology, Sanofi Pasteur Inc., Swiftwater, Pennsylvania, USA, using 109 





Enzyme-linked immunosorbent assays for antibodies to pertussis and tetanus 112 
antigens. Antibody concentrations to pertussis antigens (PT, FHA, PRN, and FIM-2,3) and 113 
to tetanus antigen were assessed at Global Clinical Immunology using enzyme-linked 114 
immunosorbent assays (see Supplemental Methods).  115 
 116 
Safety evaluation 117 
Safety measurements in the primary phase of this study included daily measurement of 118 
axillary temperatures in the evening from Day 1 (day of vaccination) to Day 5 following each 119 
vaccination; daily collection of solicited injection site reactions (from Day 1 to Day 5 following 120 
each vaccination; daily collection of solicited systemic adverse events (AEs) from Day 1 to 121 
Day 5 following each vaccination; and collection of any unsolicited AEs (i.e., spontaneously 122 
reported) from Day 1 to Day 15 following each vaccination. 123 
 124 
During the primary and booster phases, all serious AEs (SAEs) were recorded, including 125 
death due to any cause, occurring from the time of consent to 14 days (Day 1 to Day 15) 126 
following each vaccination, whether or not related to the study vaccines. Any SAE which 127 
occurred at any time outside of the follow-up period (Day 1 to Day 15) was also reported if 128 
the event was either: (1) a death or (2) an SAE that was considered by an investigator to be 129 
possibly, probably, or definitely vaccine-related. 130 
 131 
Statistical analysis 132 
The sample size of the study was calculated for the primary objective of the study using 133 
PASS 2008 software (NCSS, LLC, Kaysville, Utah) based on the binomial distribution. The 134 
main immunogenicity analyses were performed on the per protocol set (PPS) which 135 
excluded participants with protocol deviations that could potentially interfere with vaccine 136 
immunogenicity. Additional intention-to-treat immunogenicity analyses were performed on 137 
the full analysis set (FAS), which included all participants with immunogenicity results. The 138 




received at least one vaccine during the primary phase of the study and who had safety 140 
follow-up data, and in the booster phase, all participants who received at least one vaccine 141 
and who had safety follow-up data in that phase. 142 
 143 
The SPR to MCC was defined as the proportion of participants in each group with an anti-144 
MCC titer of at least 8. The percent of participants with titers ≥128 dilution was also 145 
recorded. It was predefined that it would be considered acceptable if the lower bound of the 146 
associated two-sided 95% confidence interval (CI; adjusted for multiplicity) was at least 147 
90% after two doses. For seroconversion rates, 95% CIs were calculated using the exact 148 
binomial method [13]; 95% CIs of GMTs were calculated using the t-distribution of the 149 
natural log-transformed antibody titers. For the post hoc analysis of seroconversion rates 150 
and GMT comparisons between randomized groups (MCC vaccines) were performed using 151 
Fisher exact testing and student t test after log transformation of individual titers, 152 
respectively. 153 
 154 
It was predefined that it would be considered acceptable if the lower bound of the Hib SPR 155 
two-sided 95% CI (adjusted for multiplicity) was at least 80% after three doses of DTaP5-156 
HB-IPV-Hib. A seroresponse to the pertussis antigens was defined as either any detectable 157 
concentration if pre-vaccine concentrations were <LLOQ or any detectable rise in 158 
concentration. Statistical analyses were performed using SAS® software version 9.1 (SAS® 159 




There were no clinically significant demographic differences noted between groups. Of the 164 
284 participants enrolled in the study, 54.6% (155) were male, with a mean age at enrolment 165 
of 62.1 days (range 47 to 76 days). The number of participants lost to follow-up or withdrawn 166 






Primary phase 170 
In the primary phase, results for all randomised participants were included in the analysis 171 
except those with protocol deviations that interfered with the immunogenicity evaluation 172 
(per protocol analysis). These mostly related to difficulties obtaining sufficient blood from 173 
the infants and/or scheduling visits within the permitted timelines. Infants in both groups 174 
exceeded the predefined acceptability threshold for seroprotection against meningococcus 175 
group C for the two groups (Table 2). Seroconversion rates (with titers ≥8 dilution) and 176 
GMTs were lower post-dose 1 in the MCC-CRM group (96.4% and 285.0, respectively) 177 
than in the MCC-TT group (100% and 1353.0, respectively; P<0.001 for both) (Table 2). 178 
 179 
SPRs and seroresponse rates (SRRs) for, and GMTs of antibodies to the DTaP5-HB-IPV-180 
Hib antigens following the three dose primary series for both study groups are shown in 181 
Table 3. Infants in both groups exceeded the predefined acceptability threshold for 182 
seroprotection against Hib (Table 3). SPRs or SRRs to all antigens exceeded 90% in both 183 
groups. GMTs of antibodies to the DTaP5-HB-IPV-Hib antigens were comparable in the two 184 
study groups that received different MCC vaccines with widely overlapping 95% CIs in all 185 
cases (Table 3). 186 
 187 
Booster phase 188 
A similar per-protocol analysis approach was taken in the booster phase. As in the primary 189 
phase, exclusions were mostly related to visit scheduling (numbers analysed are shown in 190 
Table 4). As expected, the participants’ responses to both Hib (PRP) and meningococcus 191 
group C antigens had waned by the time the Hib-MCC booster vaccination was administered 192 
(Table 4). This was particularly evident for meningococcus group C bactericidal antibodies in 193 
the MCC-CRM group. Responses to both antigens were boosted in both groups, although 194 




primed group (580.8 vs 3257.9; P<0.001), and the post-booster GMCs of antibodies to Hib 196 
(PRP) did not differ significantly between groups. 197 
 198 
Safety 199 
Safety data from all participants who received at least 1 study vaccine dose during the 200 
primary phase of the study and who had any safety follow-up data collected are shown in 201 
Table 5. No significant differences between rates of AEs in the two study groups were 202 
observed, and combined data are presented. There were no withdrawals due to AEs. One 203 
participant experienced 2 SAEs (severe abdominal pain; inconsolable crying) that occurred 2 204 
days after the second dose of DTaP5-HB-IPV-Hib and the first dose of MCC-CRM; these 205 
events spontaneously resolved within 2 days and were considered possibly vaccine-related 206 
by the investigator. 207 
 208 
Discussion 209 
This study was conducted primarily to demonstrate the compatibility of this DTaP5-HB-IPV-210 
Hib vaccine with two different MCC vaccines in the infant primary series that were in use in 211 
the UK at the time of this study. Although the UK has since ceased to use meningococcus 212 
group C vaccines in infants, other European countries continue to do so, although use of a 213 
single priming-dose is now more common there. The results of the present study confirm 214 
that this hexavalent combination vaccine when given to infants in an accelerated 2-, 3-, and 215 
4-month schedule along with two doses of these TT- and CRM-containing MCC, results both 216 
in satisfactory immune responses to antigens within the DTaP5-HB-IPV-Hib vaccine and is 217 
associated with high rates of seroprotection against meningococcus group C. In fact, very 218 
high seroprotection rates after a single priming dose of either MCC vaccine were also seen. 219 
Similarly, high seroprotection rates against meningococcus group C were achieved following 220 
second-year boosting, indicating effective priming and excellent levels of direct protection 221 





Immune responses to all the antigens in the DTaP5-HB-IPV-Hib combination vaccine were 224 
studied in detail, and high seroprotection rates and seroconversion rates were consistently 225 
observed (Table 3). Immunogenicity results for the DTaP5-HB-IPV-Hib antigens did not differ 226 
between groups, suggesting that the two different MCC vaccines had no observable effect 227 
on the immunogenicity of these antigens. This is especially relevant for Hib, given that 228 
previous studies using combination vaccines employing TT or CRM carrier proteins for Hib 229 
have shown an inhibition of the Hib response when coadministered with MCC [14-16], 230 
thought to be due to carrier protein induced epitopic suppression [17]. In contrast, the Hib 231 
component of DTaP5-IPV-Hib-IPV is conjugated to the outer membrane protein complex 232 
(OMPC) from N. meningitidis serogroup B (PRP–OMPC) rather than TT or CRM, and no 233 
interference was observed. Thus, any interference between MCC and Hib immunogenicity 234 
via carrier-induced epitopic suppression may be avoided.  235 
 236 
Because a randomized approach was taken to the allocation of infants to one of the two 237 
MCC vaccines, comparisons can be made between these groups despite being a post hoc 238 
analysis. The results demonstrate the superior immunogenicity of the MCC-TT vaccine used 239 
compared with the MCC-CRM vaccine. However, a previous study comparing different 240 
MCC-TT and MCC-CRM vaccines than those used in the present study showed no 241 
differences in reactogenicity or immunogenicity profiles [18]. Nevertheless, an open-label 242 
study of three MCC vaccines licenced in the UK showed that administering an MCC-TT 243 
vaccine at 4 months of age, after receipt of an MCC-CRM vaccine at 3 months of age, 244 
resulted in lower GMTs compared with receipt of an MCC-TT or MCC-CRM vaccine at both 245 
time points or receipt of the MCC-TT vaccine followed by the MCC-CRM vaccine, suggesting 246 
that MCC vaccines with different carrier proteins are not fully interchangeable [19]. Another 247 
study found that a single infant MCC-TT priming dose induced a more robust post-booster 248 
response than either one or two MCC-CRM priming doses [20]. Thus, the unequal 249 
immunogenicity results for the two MCC vaccines in the present study could be of clinical 250 




meningococcus group C strains continue to circulate, as MCC-CRM primed infants’ 252 
responses frequently waned to levels below the putative protective threshold. This 253 
observation confirms the greater immunogenicity of prime-boost conjugate schedules using 254 
the same protein at both phases [19,21]; in this case, tetanus toxoid.   255 
 256 
The safety data summarized in this report are concordant with rates of local and systemic 257 
reactions previously reported for acellular-pertussis containing vaccines and conjugate 258 
vaccines given according to this accelerated schedule [22-24]. 259 
 260 
Finally, the results of this study should be taken in the context of evolving understanding of 261 
the mechanisms of effectiveness of conjugate vaccines in general, and meningococcal 262 
vaccine, in particular. Although direct protection by induction of protective bactericidal 263 
concentrations of antibody in infants, the most frequent victims of invasive bacterial disease, 264 
has been the cornerstone of vaccine development and licensure, it is now widely 265 
appreciated that such protective immune responses induced in infancy are relatively short-266 
lived [25]. Furthermore, disease control appears to occur most reliably and effectively when 267 
circulation of invasive bacterial strains is interrupted at the population level [26]. 268 
Immunization schedules are changing in response to these new insights and the regimens 269 
being tested as part of vaccine development programs in the future are likely also to change 270 
as a result.  271 
 272 
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Completed Primary Phase (n=140) 
• Withdrew consent (n=1) 
• Lost to follow-up (n=1) 
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Entered Booster Phase (n=139) 
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Table 1 344 
Vaccine details (A) and schedule of vaccine administration and blood sampling (B). 345 
 346 
A. Vaccines administered 
Target disease Antigen (s) DTaP5-HB-IPV-Hiba,b  
Diphtheria D 15 Lf 
Tetanus T 5 Lf 
Pertussis Pertussis toxin (PT) 20 μg 
Filamentous haemagglutinin (FHA) 20 μg 
Pertactin (PRN) 3 μg 
Fimbriae types 2&3 (FIM-2,3) 5 μg 
Polio Type 1 (Mahoney) 40 D-antigen units 
Type 2 (MEF-1) 8 D-antigen units 
Type 3 (Saukett) 32 D-antigen units 
Haemophilus influenzae  
type b  
polyribosylribitol phosphate (PRP), 
outer membrane protein 
complex (OMPC) from N. meningitidis 
serogroup B (OMPC) 
PRP 3 μg  
OMPC 50 μg 
Hepatitis B HBsAg 10 μg 
(Adjuvant) Aluminium 319 μg 
aLot C3146B 
bOther licensed vaccines were used in the study, all were given as 0.5 mL intramuscular doses: 
MCC-CRM (Novartis Vaccine or Diagnostics lots 382011 & BA4559A) or MCC-TT (Baxter AG, lot 
VNS1L05A), PCV-13 (Pfizer Inc. lots F54378 & G29716), MMR (Merck & Co. Inc., Kenilworth, NJ, 
USA lots H010594 & H010453), Hib-MCC (GlaxoSmithKline, lot A76CA209A). 
 347 
B. Vaccine administration and blood sampling schedule 
Phase Primary phase Booster phase 
Visit V1 V2 V3 V4 V5 V6 
Age  2 months 3 months 4 months 5 months 12 months 13 months 
DTaP5-HB-IPV-HIB X X X    
MCC-TT (Group 1)  X X    
MCC-CRM (Group 2)  X X    
PCV-13 X  X  X  
Hib-MCC     X  
MMR     X  
Blood draw X  X X X X 
CRM: Corynebacterium diphtheriae CRM197; Hib: Haemophilus influenzae type b; MCC: 
meningococcus group C conjugate; MMR: measles, mumps, rubella; PCV: pneumococcal conjugate 
vaccine; TT: tetanus toxoid.  
DTaP5-HB-IPV-HIB, Vaxelis®, MCM Vaccine B. V., Leiden, The Netherlands; MCC-TT, NeisVac-C®, 
Baxter AG, Wien, Austria; MCC-CRM, Menjugate®, Novartis Vaccine and Diagnostics, S.R.L., Siena, 
Italy; PCV-13, Prevenar 13®, Pfizer Inc, England; Hib-MCC, Menitorix®, GlaxoSmithKline, Belgium, 









Table 2 353 
Summary of MCC serum bactericidal antibody responses per dose, per protocol set, primary 354 










 Observed response Observed response Observed response  
Endpoint p/n [95% CI] p/n [95% CI] p/n [95% CI]  
Post-dose 1 of MCC vaccine (at around 3 months of age; 28 to 44 days after Visit 1)  
% with titers  
≥8 dil  
102/102 100.0 81/84 96.4 183/186 98.4  
 [96.4, 100]  [89.9, 99.3]  [95.4, 99.7] NSb 
% with titers  
≥128 dil  
100/102 98.0 71/84 84.5 171/186 91.9  
 [93.1, 99.8]  [75.0, 91.5]  [87.0, 95.4] <0.001b 
GMT  1353.0  285.0  669.6  
  [1058.4, 1729.6]  [201.5, 403.1]  [530.2, 845.6] <0.001c 
n missing  23  27  50  
Post-dose 2 of MCC vaccine (at around 4 months of age; 28 to 44 days after Visit 2)  
% with titers  
≥8 dil  
121/121 100.0 108/109 99.1 229/230 99.6  
 [97.0, 100]  [95.0, 100]  [97.6, 100] NSb 
% with titers  
≥128 dil  
120/121 99.2 108/109 99.1 228/230 99.1  
 [95.5, 100]  [95.0, 100]  [96.9, 99.9] NSb 
GMT  2024.7  1077.4  1501.5  
  [1689.8, 2425.9]  [847.5, 1369.8]  [1288.8, 1749.3] <0.001c 
n missing  4  2  6  
CI: confidence interval; CRM: Corynebacterium diphtheriae CRM197; dil: dilution; GMT: geometric mean titer; MCC: 
meningococcus group C conjugate; n: number of participants included in the analysis; NS: not significant; p: number of 
participants with the response; TT: tetanus toxoid.   
bP value: Fisher exact test.  
cP value: Student t test on log-transformed data. 




Table 3 357 
Summary of DTaP5-HB-IPV-HIB antibody responses post-dose 3 (at around 4 months of 358 








  Observed response Observed response Observed response 
Antigen Endpoint p/n or n [95% CI] p/n or n [95% CI] p/n or n [95% CI] 
PRP 
% with conc ≥0.15 µg/mL 91/93 97.8 82/82 100.0 173/175 98.9 
  [92.4, 99.7]  [95.6, 100.0]  [95.9, 99.9] 
GMC (µg/mL)  6.44  8.21  7.22 
  [4.70, 8.83]  [6.08, 11.09]  [5.81, 8.97] 
HBsAg 
% with conc ≥10 mIU/mL 90/93 96.8 79/82 96.3 169/175 96.6 
  [90.9, 99.3]  [89.7, 99.2]  [92.7, 98.7] 
GMC (mIU/mL)  195.1  247.7  218.2 
  [150.7, 252.7]  [186.3, 329.3]  [180.4, 264.0] 
Diphtheria 
% with conc ≥0.01 IU/mL 125/125 100.0 104/104 100.0 229/229 100.0 
  [97.1, 100.0]  [96.5, 100.0]  [98.4, 100] 
% with conc ≥0.1 IU/mL 85/125 68.0 77/104 74.0 162/229 70.7 
  [59.1, 76.1]  [64.5, 82.1]  [64.4, 76.5] 
GMC (IU/mL)  0.198  0.220  0.208 
  [0.165, 0.237]  [0.181, 0.268]  [0.182, 0.237] 
Tetanus 
% with conc ≥0.01 IU/mL 122/122 100.0 105/105 100.0 227/227 100.0 
  [97.0, 100.0]  [96.5, 100.0]  [98.4, 100] 
% with conc ≥0.1 IU/mL 122/122 100.0 105/105 100.0 227/227 100.0 
  [97.0, 100.0]  [96.5, 100.0]  [98.4, 100] 
GMC (IU/mL)  1.03  0.95  0.99 
  [0.90, 1.17]  [0.82, 1.10]  [0.90, 1.09] 
Pertussis  
PT 
% with seroresponse [2] 99/100 99.0 75/75 100.0 174/175 99.4 
 [94.6, 100.0]  [95.2, 100.0]  [96.9, 100.0] 
GMC (EU/mL) 112 131.5 89 133.3 201 132.3 
  [117.2, 147.6]  [118.3, 150.2]  [121.8, 143.7] 
Pertussis  
FHA 
% with seroresponse [2] 91/100 91.0 67/74 90.5 158/174 90.8 
 [83.6, 95.8]  [81.5, 96.1]  [85.5, 94.7] 
GMC (EU/mL) 112 50.4 88 50.1 200 50.2 
  [44.8, 56.6]  [43.7, 57.4]  [46.0, 54.9] 
Pertussis  
PRN 
% with seroresponse [2] 95/100 95.0 66/73 90.4 161/173 93.1 
 [88.7, 98.4]  [81.2, 96.1]  [88.2, 96.4] 
GMC (EU/mL) 112 90.4 87 106.8 199 97.2 
  [73.2, 111.7]  [83.7, 136.3]  [83.0, 114.0] 
Pertussis  
FIM-2,3 
% with seroresponse [2] 96/100 96.0 72/75 96.0 168/175 96.0 
 [90.1, 98.9]  [88.8, 99.2]  [91.9, 98.4] 
GMC (EU/mL) 112 401.7 89 441.7 201 419.0 





% with titers ≥8  114/114 100.0 95/95 100.0 209/209 100.0 
 [96.8, 100.0]  [96.2, 100.0]  [98.3, 100] 
GMT   214.0  257.9  232.9 





% with titers ≥8 106/106 100.0 89/89 100.0 195/195 100.0 
  [96.6, 100.0]  [95.9, 100.0]  [98.1, 100] 
GMT (dil)  385.2  400.6  392.2 





% with titers ≥8 90/90 100.0 74/74 100.0 164/164 100.0 
  [96.0, 100.0]  [95.1, 100.0]  [97.8, 100.0] 
GMT (dil)  502.2  405.1  455.8 
  [370.2, 681.4]  [284.9, 576.0]  [362.6, 573.1] 
CI: confidence interval; CRM: Corynebacterium diphtheriae CRM197; dil: dilution; EU: ELISA units FHA: filamentous haemagglutinin; 
FIM-= fimbriae; GMC: geometric mean concentration; GMT: geometric mean titer; HBsAg: hepatitis B surface antigen; IU: 
international units; MCC: meningococcus group C conjugate; n: number of participants included in the analysis; p: number of 
participants with the response; PRN: pertactin; PRP: polyribosylribitol phosphate; PT: pertussis toxin; TT: tetanus toxoid.  
[2] Pertussis seroresponse was defined as: (1) if the pre-vaccination antibody concentration was < lower limit of quantification 
(LLOQ), then the post-vaccination antibody concentration was to be ≥ LLOQ; (2) if the prevaccination antibody concentration was 






Table 4 362 
SPRs and GMTs for Hib and meningococcus group C before and 1 month after the Hib-MCC 363 
vaccine booster at 12 months, per protocol analysis, booster phase (N=222).a  364 
 365 






 Observed response Observed response  Observed response 
Antigen Endpoint p/n [95% CI] p/n [95% CI] p/n [95% CI] P value 
Hib  
(PRP) 
Pre-Hib-MCC vaccine  
% with conc ≥0.15 µg/mL 77/82 93.9 83/87 95.4 160/169 94.7  
  [86.3, 98.0]  [88.6, 98.7]  [90.1, 97.5]  
% with conc ≥1.0 µg/mL 45/82 54.9 49/87 56.3 94/169 55.6  
  [43.5, 65.9]  [45.3, 66.9]  [47.8, 63.2]  
GMC (µg/mL)  1.09  1.18  1.14  
  [0.81, 1.45]  [0.90, 1.55]  [0.93, 1.38]  
Post-Hib-MCC vaccine  
% with conc ≥0.15 µg/mL 110/110 100.0 106/106 100.0 216/216 100  
  [96.7, 100.0]  [96.6, 100.0]  [98.3, 100]  
% with conc ≥1.0 µg/mL 109/110 99.1 106/106 100.0 215/216 99.5  
  [95.0, 100]  [96.6, 100.0]  [97.4, 100.0]  
GMC (µg/mL)  100.19  121.00  109.91  
  [81.05, 123.86]  [101.11, 144.80]  [95.66, 126.28]  
MCC Pre-Hib-MCC vaccine  
% with titer ≥8 dil 74/89 83.1 38/94 40.4 112/183 61.2 <0.001* 
  [73.7, 90.2]  [30.4, 51.0]  [53.7, 68.3]  
% with titer ≥128 dil 36/89 40.4 15/94 16.0 51/183 27.9 <0.001* 
  [30.2, 51.4]  [9.2, 25.0]  [21.5, 35.0]  
GMT (dil)  50.3  8.7  20.5 <0.001** 
  [34.4, 73.4]  [5.9, 12.9]  [15.2, 27.5]  
Post-Hib-MCC vaccine  
% with titer ≥8 dil 109/109 100 107/110 97.3 216/219 98.6 NS* 
  [96.7, 100]  [92.2, 99.4]  [96.0, 99.7]  
% with titer ≥128 dil 108/109 99.1 105/110 95.5 213/219 97.3 NS* 
  [95.0, 100]  [89.7, 98.5]  [94.1, 99.0]  
GMT (dil)  3257.9  580.8  1370.1 <0.001** 
  [2597.4, 4086.3]  [432.7, 779.5]  [1102.4, 1702.9]  
CI: confidence interval; CRM: Corynebacterium diphtheriae CRM197; dil: dilution; GMC: geometric mean concentration; GMT: 
geometric mean titer; Hib: Haemophilus influenzae type b; MCC: meningococcus group C conjugate; n: number of participants 
included in the analysis; NS: not significant; p: number of participants with the response; PRP: polyribosylribitol phosphate; SPR: 
seroprotection rate; TT: tetanus toxoid. 
aPrevaccination values were obtained prior to vaccination on the same day that the vaccine was administered. 
*P value: Fisher exact test. **P value: Student t test on log-transformed data. 
 366 





Table 5  369 
Safety data collected during the primary phase of the study (Day 1 through 15 days after last 370 
vaccination), safety set (N=284). 371 
 372 




Number (%) of participants:   
  With no AE 6 (2.1) 
  With ≥1 AEs 278 (97.9) 
       ≥1 vaccine-related AE 277 (97.5) 
ISR (day 1 to day 15) 253 (89.1) 
    ISR at DTaP5-HB-IPV-HIB site (day 1 to day 15) 250 (88.0) 
      Solicited ISR (day 1 to day 5) 250 (88.0) 
        Injection site erythema 193 (68.0) 
        Injection site pain 184 (64.8) 
        Injection site swelling 140 (49.3) 
      Unsolicited ISR (day 1 to day 15) 25 (8.8) 
    ISR at MCC site (day 1 to day 15) 197 (69.4) 
      Solicited ISR (day 1 to day 5) 196 (69.0) 
        Injection site erythema 145 (51.1) 
        Injection site pain 124 (43.7) 
        Injection site swelling 91 (32.0) 
      Unsolicited ISR (day 1 to day 15) 8 (2.8) 
Systemic AE (day 1 to day 15) 274 (96.5) 
    Solicited systemic AE (day 1 to day 5) 270 (95.1) 
    Unsolicited systemic AE (day 1 to day 15) 128 (45.1) 
    Vaccine-related systemic AEa 272 (95.8) 
      Solicited systemic AE (day 1 to day 5) 270 (95.1) 
        Crying 236 (83.1) 
        Decreased appetite 181 (63.7) 
        Irritability 240 (84.5) 
        Pyrexia 31 (10.9) 
        Somnolence 226 (79.6) 
        Vomiting 126 (44.4) 
      Unsolicited systemic AE (day 1 to day 15) 75 (26.4) 
SAE (day 1 to day 15) 10 (3.5) 
Vaccine-related SAE 1 (0.4) 
Death 0 (0.0) 
Withdrawn due to AEb 0 (0.0) 
Withdrawn due to vaccine-related SAEa,b 0 (0.0) 
(S)AE: (serious) adverse event; ISR: injection site reaction; MCC: meningococcus group 
C conjugate; N: number vaccinated.  
aDetermined by the investigator to be related to the vaccine. 




Supplemental Methods 374 
Micrometabolic Inhibition Tests for Antibodies to Diphtheria 375 
Serial dilutions of human sera were mixed with diphtheria challenge toxin and incubated with 376 
Vero cells that were sensitive to the toxin. Neutralizing antibodies specific to diphtheria toxin 377 
contained in the serum samples bound to and neutralized the toxin. The neutralized toxin did 378 
not affect cellular viability, therefore, the cultured cells continued to metabolize and release 379 
carbon dioxide (CO2), reducing the potential of hydrogen (pH) of the culture medium. Cell 380 
survival correlated with the change in the colour of the pH indicator (phenol red to yellow at 381 
pH 7.0) contained in the medium. In the absence of neutralizing antibodies, the challenge 382 
toxin reduced cellular metabolism and CO2 production, therefore, the pH did not decrease 383 
and a colour change was not detected. 384 
Results were reported in international unit (IU)/mL by inclusion of the World Health 385 
Organization (WHO) International Standard for Diphtheria Antitoxin in the assay. The lower 386 
limit of quantitation (LLOQ) was 0.005 IU/mL. 387 
Micrometabolic Inhibition Tests for Antibodies to Poliovirus 388 
Serial dilutions of sera were mixed with challenge poliovirus and incubated with cultured Vero 389 
cells that were sensitive to poliovirus. Specific neutralizing antibodies contained in the sera 390 
bound to and neutralized the challenge poliovirus. The neutralized poliovirus did not affect 391 
cellular viability, and these cells continued to metabolize and release CO2, reducing the pH of 392 
the culture medium. Cell survival correlated with the change in the pH indicator (phenol red to 393 
yellow at pH 7.0) contained in the medium. In the absence of neutralizing antibodies, the 394 
challenge poliovirus reduced cellular metabolism and CO2 production; therefore, the pH did 395 
not decrease and a colour change was not detected. The poliovirus micrometabolic inhibition 396 
test measured the functional serum antibody response to poliovirus by utilizing Vero cells 397 
(African green monkey kidney cells) and wild type poliovirus strains 1, 2, and 3 (Mahoney, 398 
MEF-1, and Saukett, respectively) as the challenge virus. The Kärber method* was used to 399 
determine the serum dilution that neutralized 50% of the challenge virus. 400 
Results were expressed as titers (1:dil). The LLOQ for polio is 4 and the upper limit of 401 
quantitation (ULOQ) is 65536 (1:dil). 402 
Enzyme-linked Immunosorbent Assays for Antibodies to Pertussis  403 
Purified pertussis antigen (PT, FHA, PRN or FIM-2,3) was adsorbed to the wells of a 404 
microtiter plate. Diluted serum samples (test samples, reference standards and quality-control 405 
samples) were incubated in the wells. Specific pertussis antibodies in the serum samples 406 
bound to the immobilized pertussis antigen to form antigen-antibody complexes. Unbound 407 
antibodies were washed from the wells, and enzyme-conjugated anti-human immunoglobulin 408 
G was added. The enzyme conjugate bound to the antigen-antibody complex. Excess 409 
conjugate was washed away and a specific colorimetric substrate was added. Bound enzyme 410 
catalysed a hydrolytic reaction causing colour development. The intensity of the generated 411 
colour was proportional to the amount of specific antibody bound to the wells. The results 412 
were read on a spectrophotometer (ELISA plate reader). A reference standard serum 413 
assayed on each plate was used to calculate the amount of specific PT, FHA, PRN, or FIM 414 
antibody in the test samples in ELISA unit (EU)/mL by comparison to the reference standard 415 
curves. 416 
The LLOQ for PT, PRN, and FIM was 4 EU/mL and for FHA was 3 EU/mL. 417 
Enzyme-linked Immunosorbent Assays for Antibodies to Tetanus 418 
Purified tetanus antigen was adsorbed to the wells of a microtiter plate. Diluted serum 419 
samples (test samples, reference standard, and quality-control samples) were incubated in 420 
the wells. Specific antibodies in the serum samples bound to the immobilized antigen. 421 
Unbound antibodies were washed from the wells and enzyme-conjugated anti-human 422 
immunoglobulin G was added. The enzyme conjugate bound to the antigen-antibody 423 
complex. Excess conjugate was washed away and a specific colorimetric substrate was 424 
added. Bound enzyme catalysed a hydrolytic reaction which caused colour development. The 425 
intensity of the generated colour was proportional to the amount of specific antibody bound to 426 
the wells. The results were read on a spectrophotometer (ELISA plate reader). A reference 427 




amount of specific anti-tetanus antibody in the units assigned by the reference standard 429 
(IU/mL of serum). 430 
The LLOQ for tetanus is 0.01 IU/mL. 431 
 432 
*Ramakrishnan MA. Determination of 50% endpoint titer using a simple formula. World J Virol 433 
2016;5(2):85–6. 434 
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